Globally, venture capital firms invested over $52 billion into biotech startups, counting investments from seed to series C. The largest proportion of funding went to platform-based therapeutics, bringing in $34.6 billion in total, while other therapeutics accounted for $17.2 billion in funding.
Here are five platform-based startup types to watch, as they received the most VC investment:
- Cell therapy represented $7.7 billion of total funding.
- Next-generation gene therapies brought in $7.6 billion in funding.
- Precision medicine companies got $4.5 billion in funding.
- Machine-learning-enabled drug discovery brought in $4.4 billion.
- Startups focusing on hard-to-hit targets, or “undruggable” targets, got $4 billion in funding.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
